Today: 9 April 2026
Subscribe
Browse Category

NYSE:ABBV 30 July 2025 - 28 November 2025

AbbVie Stock (ABBV) Today: Skyrizi’s Canada Win, Dividend Hike and Big-Money Moves — November 28, 2025

AbbVie Stock (ABBV) Today: Skyrizi’s Canada Win, Dividend Hike and Big-Money Moves — November 28, 2025

AbbVie closed Friday at $227.70, up 0.02% after a flat session. Canada’s drug agency recommended reimbursement for Skyrizi in ulcerative colitis, and AbbVie finalized a pricing deal with the national negotiator. Institutional investors adjusted positions, with some funds increasing and others reducing stakes. The stock’s year-to-date gain stands near 30–33%.
28 November 2025
·
AbbVie (ABBV) Stock Today, November 26, 2025: Share Price Dip Amid FDA Win, Medicare Drug Price Cuts and Bullish Options Signals

AbbVie (ABBV) Stock Today, November 26, 2025: Share Price Dip Amid FDA Win, Medicare Drug Price Cuts and Bullish Options Signals

AbbVie shares fell 1.9% to $227.41 in early U.S. trading Wednesday, pulling back from recent highs after a strong run. The drop follows new Medicare drug price cuts targeting two AbbVie drugs and comes days after FDA approval of EPKINLY combo therapy for follicular lymphoma. Year to date, the stock is up about 30%.
26 November 2025
··
AbbVie (ABBV) Stock Today: Price, Analyst Views, Medicare News and New Biotech Award – November 25, 2025

AbbVie (ABBV) Stock Today: Price, Analyst Views, Medicare News and New Biotech Award – November 25, 2025

AbbVie shares closed at $231.80 on Tuesday, up 1.0%, after U.S. Medicare confirmed plans to negotiate prices on 15 drugs, including AbbVie’s Linzess. The stock saw higher-than-average volume and remains about 5% below its 52-week high. Analysts gave mixed views, with a “Moderate Buy” consensus and a $241.85 average price target. AbbVie also launched a new biotech award program in Quebec.
25 November 2025
·
AbbVie Stock Today (ABBV): Near Record Highs on New Cancer Approval, Raised Guidance and Dividend Hike – November 23, 2025

AbbVie Stock Today (ABBV): Near Record Highs on New Cancer Approval, Raised Guidance and Dividend Hike – November 23, 2025

AbbVie closed at $236.28 on November 21, 2025, near its 52-week high and up about 31% year to date. Q3 revenue rose 9.1% to $15.8 billion, led by immunology and neuroscience, while GAAP EPS dropped sharply due to a $2.7 billion R&D charge. The FDA granted full approval for EPKINLY in follicular lymphoma on November 18. AbbVie raised its 2025 revenue and EPS guidance and approved a 5.5% dividend hike for 2026.
23 November 2025
··
Stocks Slip as Tech Wobble Returns; Layoffs Spike and Tariff Showdown Clouds Outlook — Stock Market Today (Nov. 6, 2025)

Stock Market Today (Nov. 11, 2025): Dow Closes at a Record as AI Shares Stumble; FTSE 100 Hits New High on BoE Cut Bets

The Dow Jones closed at a record 47,927.96 on Nov. 11, 2025, up 1.18%, while the Nasdaq fell 0.25% as Nvidia dropped nearly 3% after SoftBank revealed a $5.8 billion stake sale. The S&P 500 edged higher. In Europe, the FTSE 100 hit a record near 9,900, boosted by Vodafone’s first dividend increase in eight years and rising bets on Bank of England rate cuts.
11 November 2025
········
AbbVie’s Bull Run: Why This $400B Pharma Giant’s Stock Is Just Getting Started

AbbVie’s Bull Run: Why This $400B Pharma Giant’s Stock Is Just Getting Started

AbbVie reported Q3 2025 revenue of $15.78 billion, up 9.1% year-over-year, and raised its full-year EPS outlook after new drugs offset Humira’s decline. Shares traded near $228 in late October, up 28% year-to-date, and the board approved a 5.5% dividend increase for 2026. Skyrizi and Rinvoq sales surged, while the FDA expanded Rinvoq’s indications. AbbVie also announced over $10 billion in acquisitions and new manufacturing investments.
31 October 2025
··
AbbVie Stock Skyrocketing? Analysts Say This $230 Biotech Giant Is Just Getting Started

AbbVie (ABBV) Stock Up 28% YTD as New Drug Wins and Analyst Upgrades Fuel Optimism

AbbVie shares trade near $229, up 28% year-to-date and outperforming the S&P 500 healthcare index. The stock hit a record high in late September after a patent settlement extended U.S. exclusivity for Rinvoq until 2037. AbbVie announced a $2.7 billion R&D write-off in October, cutting profit guidance. FDA expanded Rinvoq’s use Oct. 13; a recent trial showed Rinvoq outperformed Humira in rheumatoid arthritis.
23 October 2025
·
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 20.10.2025

Fed Chair Jerome Powell signaled the central bank may soon pause its balance-sheet runoff, hinting at an end to quantitative tightening. The move could ease monetary conditions and support stocks, though risks remain if earnings weaken. AbbVie and Abbott Laboratories continue to deliver steady dividend growth, appealing to long-term income investors. Walmart’s new OpenAI partnership and AI-driven features have lifted its shares despite sector headwinds.
20 October 2025
···
Obesity Pill Breakthrough, Gene Therapy Triumph & Billion-Dollar Psychedelic Bet – Global Biotech & Health Highlights (Aug 26–27, 2025)

Obesity Pill Breakthrough, Gene Therapy Triumph & Billion-Dollar Psychedelic Bet – Global Biotech & Health Highlights (Aug 26–27, 2025)

Eli Lilly’s oral weight-loss drug orforglipron cut body weight by up to 10.5% in a Phase 3 trial for obese diabetics, with all doses meeting primary endpoints over 72 weeks. The FDA granted full approval to Precigen’s Papzimeos, the first gene therapy for adult recurrent respiratory papillomatosis. AbbVie agreed to acquire a psychedelic-based depression drug from Gilgamesh Pharmaceuticals in a deal worth up to $1.2 billion.
27 August 2025
·····
Billion-Dollar Pharma Deals, Biotech Breakthroughs & Global Health Alerts – Biotech & Health News Roundup (Aug 25–26, 2025)

Billion-Dollar Pharma Deals, Biotech Breakthroughs & Global Health Alerts – Biotech & Health News Roundup (Aug 25–26, 2025)

AbbVie agreed to acquire Gilgamesh Pharmaceuticals’ experimental psychedelic depression drug for up to $1.2 billion, planning to advance it to Phase 3 trials. Japan’s Terumo will buy UK-based OrganOx for $1.5 billion, gaining organ preservation technology. LB Pharma filed for a $100 million IPO, the first biotech IPO in six months. Arnatar Therapeutics raised $52 million to develop RNA therapy for Alagille syndrome.
26 August 2025
··
Breakthrough Drugs, Big Deals & Public Health Alerts – Biotech and Health News Roundup (Aug 22–23, 2025)

Breakthrough Drugs, Big Deals & Public Health Alerts – Biotech and Health News Roundup (Aug 22–23, 2025)

The FDA approved Ionis Pharmaceuticals’ Dawnzera as the first RNA-targeted therapy to prevent hereditary angioedema attacks, priced at about $57,462 per dose. AbbVie’s Rinvoq met key endpoints in a second Phase 3 alopecia areata trial, while Scholar Rock’s apitegromab showed significant motor gains in spinal muscular atrophy. Gilead’s Kite Pharma will acquire Interius BioTherapeutics for $350 million.
23 August 2025
·······
From Foldable Phones to Moon Missions: The Biggest Tech News Roundup (July 29–30, 2025)

From Foldable Phones to Moon Missions: The Biggest Tech News Roundup (July 29–30, 2025)

Samsung unveiled the Galaxy Z Fold7 at $1,999 and the Flip7 FE at $899, with the Fold7 26% thinner and 10% lighter than last year’s model. Opera filed an antitrust complaint in Brazil against Microsoft over Edge’s default status. Sony sued Tencent, alleging Light of Motiram copied Horizon Zero Dawn. Figma raised its IPO price range, targeting an $18.8 billion valuation.
30 July 2025
·············
1 … 3 4 5

Stock Market Today

  • Ares Management (ARES) Share Price Drops 37% YTD, Valuation Concerns Raised
    April 8, 2026, 8:05 PM EDT. Ares Management's (ARES) shares have fallen 37% year-to-date despite solid long-term gains, highlighting shifting investor sentiment in alternative asset managers. The stock trades around $104.83, but valuation models suggest a lower intrinsic value of $87.61, implying a 19.7% overvaluation. Metrics like book value ($12.68 per share) and earnings per share ($5.79) underpin this analysis. Ares' high return on equity (27.6%) contrasts with a cost of equity at $1.93, yet excess returns indicate value creation may not justify the current share price. Investors are advised to weigh fee-based revenue models against market risk reassessments. Simply Wall St rates ARES 0/6 on valuation checks, signaling caution amid volatile market conditions.

Latest article

Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

8 April 2026
IREN shares rose 1.8% to $35.74 Wednesday as investors assessed its $6 billion share program and shift from bitcoin mining to AI cloud services. The company’s revenue fell to $184.7 million last quarter, with a net loss of $155.4 million. IREN recently announced a five-year, $9.7 billion AI cloud deal with Microsoft. Options trading volume hit 103,000 contracts Tuesday, with sentiment described as mixed.
Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

8 April 2026
Amazon closed at $213.77 Tuesday, with BNP Paribas maintaining a $320 price target, citing strong AI demand despite Amazon’s planned $200 billion capex for 2026. The company’s February forecast of higher spending sent shares down 11.5% after hours, even as AWS revenue rose 24% to $35.6 billion in the December quarter. Alphabet and Microsoft are also ramping up AI infrastructure spending.
Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

8 April 2026
The Sensex surged 2,946 points to 77,562.90 on Wednesday, its best day in five years, as a U.S.-Iran ceasefire and steady RBI rates pushed Indian markets higher. Brent crude fell 14.4% to $93.49 a barrel, easing pressure on the rupee, which rose 0.5% to 92.58 per dollar. All 16 major sectors gained, led by financials and auto stocks. The RBI kept its repo rate at 5.25% and forecast slower growth ahead.
Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

8 April 2026
Stock Yards Bank & Trust Co. increased its Netflix stake by 1,141.9% to 29,074 shares in Q4, while Ethos Capital Management disclosed a new 19,610-share position worth $1.84 million. The moves come ahead of Netflix’s April 16 earnings report and follow a Goldman Sachs upgrade to Buy with a $120 target. Insiders Reed Hastings and Greg Peters sold shares earlier this year under preset trading plans. Netflix last traded at $98.82.
Alphabet Stock (GOOG, GOOGL) Faces Split Fund Bets Ahead of Earnings After Fresh 13F Reports

Alphabet Stock (GOOG, GOOGL) Faces Split Fund Bets Ahead of Earnings After Fresh 13F Reports

8 April 2026
Zevenbergen Capital increased its Alphabet Class A share holdings by 27.4% in Q4, while Lombard Odier and Empirical Wealth Management reduced their Class C positions, according to April 7 filings. Alphabet will report first-quarter results on April 29. GOOG and GOOGL traded near $304 before Wednesday’s U.S. open. The filings reflect holdings as of December 31 and may not show current positions.
Go toTop